Evaluation of PK and Safety of D-0120 and Allopurinol

A Phase I, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic Interactions Between D-0120 and Allopurinol in Healthy Adult Subjects

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05360628

Enrollment

Registered

2022-05-04

Start date

2021-11-01

Completion date

2022-07-23

Last updated

2023-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects

Interventions

DRUGD-0120 in combination with Allopurinol

noted above

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Intervention model description

D0120 Allopurinol

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy subjects between the ages of 18-55 * Required evaluation by Investigator for screening and enrollment * Agreement and compliance with the study and follow-up procedures

Exclusion criteria

* Significant medical history or current comorbidly determined by the Investigator. * Pregnant or nursing women

Design outcomes

Primary

Measure	Time frame	Description
Type, incidence, severity and attribution of AEs.	14 days	Evaluation of safety between D-0120 and Allopurinol
Plasma concentration of D-0120 and Allopurinol	14 days	Evaluation of exposure between D-0120 and Allopurinol

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026